Trial Profile

Phase 2 Double-Blind, Randomized, Placebo Controlled, Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV-2100 (Primary)
Indications Migraine; Neuropathic pain
Focus Registrational; Therapeutic Use
Sponsors Biohaven Pharmaceutical Holding Company; Biohaven Therapeutics

Most Recent Events

20 Feb 2025 Status changed from recruiting to active, no longer recruiting.
12 Nov 2024 According to Biohaven media release, this trial is designed to support registration with FDA-accepted co-primary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours.
30 Sep 2024 Status changed from not yet recruiting to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com